Abstract
Cognitive disorders are an important group of disorders affecting the brain for which currently used drugs are often of low efficacy and mainly of symptomatic value. There is increasing evidence suggesting that epigenetic changes in gene expression underlie cognitive disorders. Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs, that reverse epigenetic changes in gene expression. At present most work on epigenetic drugs focuses on two types of drugs: histone deacetylase (HDAC) inhibitors, and drugs _targeting DNA methylation. This article describes the role of epigenetic drugs in treating cognitive disorders, focusing on Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Epigenetic drugs may improve the clinical management of patients with cognitive disorders.
Keywords: Cognitive, DNA methylation, epigenetic drug, histone deacetylase.
Current Pharmaceutical Design
Title:Epigenetic Drugs in Cognitive Disorders
Volume: 20 Issue: 11
Author(s): Jacob Peedicayil
Affiliation:
Keywords: Cognitive, DNA methylation, epigenetic drug, histone deacetylase.
Abstract: Cognitive disorders are an important group of disorders affecting the brain for which currently used drugs are often of low efficacy and mainly of symptomatic value. There is increasing evidence suggesting that epigenetic changes in gene expression underlie cognitive disorders. Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs, that reverse epigenetic changes in gene expression. At present most work on epigenetic drugs focuses on two types of drugs: histone deacetylase (HDAC) inhibitors, and drugs _targeting DNA methylation. This article describes the role of epigenetic drugs in treating cognitive disorders, focusing on Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Epigenetic drugs may improve the clinical management of patients with cognitive disorders.
Export Options
About this article
Cite this article as:
Peedicayil Jacob, Epigenetic Drugs in Cognitive Disorders, Current Pharmaceutical Design 2014; 20 (11) . https://dx.doi.org/10.2174/13816128113199990526
DOI https://dx.doi.org/10.2174/13816128113199990526 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Treatments of Opiate Dependence
Current Pharmaceutical Design Beyond the "Lock and Key" Paradigm: _targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology <i>Valeriana spp</i>.: Biological Activities and New <i>In vitro</i> and <i>In vivo</i> Perspectives
Current Bioactive Compounds Hypotensive Effect of Hydroalcoholic Ziziphus jujuba Extract on Normotensive Rats
Current Nutrition & Food Science Dopexamine After Heart Surgery: An Uncommonly Used, Though Useful Inotropic Agent
Recent Patents on Cardiovascular Drug Discovery Controlled Delivery of Biotechnological Products
Current Pharmaceutical Biotechnology Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology A Review Study about the Effect of Chitosan Nanocarrier on Improving the Efficacy of Amphotericin B in the Treatment of Leishmania from 2010 to 2020
Current Drug Delivery Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry Flaxseed and Endotoxic Shock
Current Pharmaceutical Design Citric Acid: A Green Bioorganic Catalyst for One-Pot Three-Component Synthesis of 2,3-dihydroquinazoline-4 (1H)-ones
Current Organocatalysis Efficacy and Safety of H1-Antihistamines: An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Ephedrine Analysis in Real Urine Sample via Solvent Bar Microextraction Technique Coupled with HPLC-UV and Chemometrics
Current Pharmaceutical Analysis AMPA Glutamate Receptors and Neuropathic Pain
Mini-Reviews in Medicinal Chemistry Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology